更新于：2024-11-04

Escitalopram Oxalate

草酸艾司西酞普兰

更新于：2024-11-04

概要

概要

基本信息

简介Escitalopram 以商品名 Esertia 销售，是一种小分子药物，可作为选择性 5-羟色胺再摄取抑制剂 (SSRI)。它以 SERT-5 转运蛋白为靶点，该靶点负责突触间隙中血清素的再摄取。通过抑制 SERT-5 转运蛋白，Escitalopram增加了大脑中血清素的细胞外浓度，这被认为是其治疗效果的潜在机制。Escitalopram还被批准用于治疗抑郁症，并已被证明可有效减少焦虑症和恐慌症的症状。它也被用于其他疾病，如强迫症和创伤后应激障碍。该药由 H. Lundbeck 开发，于 2002 年 8 月 14 日在美国首次获得批准，随后陆续在中国和日本获批上市。

药物类型

小分子化药

别名

Cipralex、Entact、Escitalopram

+ [16]

靶点

5-HT receptor x SERT

作用机制

5-HT receptor拮抗剂(5-羟色胺受体拮抗剂)、SERT抑制剂(5-羟色胺转运体抑制剂)

治疗领域

其他疾病

在研适应症

强迫症社交恐怖症抑郁症+ [3]

非在研适应症

获得性免疫缺陷综合征行为障碍创伤性脑损伤+ [3]

原研机构

H. Lundbeck A/S

在研机构

Yoshitomi Co., Ltd.

Generic Health Pty Ltd.

H. Lundbeck A/S

+ [4]

非在研机构

Lundbeck LLC

最高研发阶段批准上市

首次获批日期

美国 (2002-08-14),

重度抑郁症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C22H23FN2O5

InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N

CAS号219861-08-2

关联

357

项与草酸艾司西酞普兰相关的临床试验

IRCT20240803062623N1 / SuspendedIIT

Bioequivalence study of two Escitalopram 20 mg FC Tablet manufactured by tadbir kalaye jam company in comparison with Brand

开始日期2024-11-05

申办/合作机构-

CTRI/2024/10/074594 / Not yet recruitingN/AIIT

Effectiveness of adjuvant Positive Psychotherapy on illness severity and wellbeing in Escitalopram non-responder patients with moderate to severe Depression: A Randomized Control Trial - NIL

开始日期2024-10-02

申办/合作机构-

NCT05603104 / Recruiting临床3期IIT

A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros. When diagnosed with one of these disorders, patients are prescribed psychotropic medication such as antidepressants, mood stabilisers or antipsychotics. It is unknown whether this first-line treatment will be successful. After this first-line treatment fails, usually a second-line treatment is initiated, and when this is not successful either a third-line treatment is initiated. Third-line treatments are quite successful, especially when compared to second-line treatments. The research question is whether the third-line treatments (early-intensified treatments) would be more efficacious than the current second-line treatments (treatment as usual) for schizophrenia, bipolar and major depressive disorders. If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments and adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs.

开始日期2024-09-30

申办/合作机构

University Medical Center of Utrecht

[+1]

100 项与草酸艾司西酞普兰相关的临床结果

登录后查看更多信息

100 项与草酸艾司西酞普兰相关的转化医学

登录后查看更多信息

100 项与草酸艾司西酞普兰相关的专利（医药）

登录后查看更多信息

208

项与草酸艾司西酞普兰相关的文献（医药）

2024-09-19·World Journal of Psychiatry

Shugan Jieyu capsule effects on peripheral blood micro-124, micro-132, and brain-derived neurotrophic factor in patients with mild to moderate depression.

Article

作者: Chen, Chun-Liang ; Wang, Ting-Ting ; Zhao, Qiang ; Zhang, Xian ; Gu, Hui-Zhong ; Liu, Yang ; Tang, Hua-Fei ; Ma, Rui ; Jiang, Feng

BACKGROUND:

To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124, miR-132, and brain-derived neurotrophic factor (BDNF) levels in patients with mild to moderate depression following coronary artery intervention [percutaneous coronary intervention (PCI)] for coronary heart disease.

AIM:

To evaluate the therapeutic efficacy of Shugan Jieyu capsules and their effects on the peripheral blood levels of miR-124, miR-132, and BDNF in patients with mild to moderate depression following PCI for coronary heart disease.

METHODS:

Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305^th Hospital of the People's Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups: Experimental (treated with Shugan Jieyu capsules) and control (treated with escitalopram oxalate tablets). This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression (HAMD-17) scores, metabolic equivalents, low-density lipoprotein cholesterol, BDNF, high-sensitivity C-reactive protein levels, miR-124 and miR-132 levels, distribution of immune-related lymphocyte subsets, and traditional Chinese medicine syndrome scores before and after 6 weeks of treatment.

RESULTS:

No significant difference was observed in any index between the two groups before treatment (P > 0.05). After treatment, the total efficacy rates were 93.33% and 90.00% in the experimental and control groups, respectively. Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group (P < 0.05). No significant difference was observed in the metabolic equivalents between the two groups before and after treatment (P > 0.05). The levels of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and miR-132 were significantly lower, whereas those of miR-124, BDNF, CD3+T lymphocytes, CD3+CD4+T helper lymphocytes, and CD3+CD4+/CD3+CD8+ cells were significantly higher in the experimental group compared to the control group (P < 0.05). The incidence of adverse reactions during experimental group was significantly lower than that in control group (P < 0.05).

CONCLUSION:

Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI, and its mechanism may contribute to the regulation of miR-124, miR-132, BDNF levels, and lymphoid immune cells.

2024-07-01·JOURNAL OF CHROMATOGRAPHY A

Design and synthesis of S-citalopram-imprinted polymeric sorbent: Characterization and application in enantioselective separation

Article

作者: Alnoman, Rua B. ; Alharbi, Hussam Y. ; Aljohani, Majed S. ; Monier, M. ; Tawfik, Eman H.

The current work describes the efficient creation and employment of a new S-citalopram selective polymeric sorbent, made from poly(divinylbenzene-maleic anhydride-styrene). The process began by using suspension polymerization technique in the synthesis of poly(styrene-maleic anhydride-divinylbenzene) microparticles. These were then modified with ethylenediamine, developing an amido-succinic acid-based polymer derivative. The S-citalopram, a cationic molecule, was loaded onto these developed anionic polymer particles. Subsequently, the particles were post-crosslinked using glyoxal, which reacts with the amino group residues of ethylenediamine. S-citalopram was extracted from this matrix using an acidic solution, which also left behind stereo-selective cavities in the S-citalopram imprinted polymer, allowing for the selective re-adsorption of S-citalopram. The attributes of the polymer were examined through methods such as ¹³C NMR, FTIR, thermogravemetric and elemental analyses. SEM was used to observe the shapes and structures of the particles. The imprinted polymers demonstrated a significant ability to adsorb S-citalopram, achieving a capacity of 878 mmol/g at a preferred pH level of 8. It proved efficient in separating enantiomers of (±)-citalopram via column methods, achieving an enantiomeric purity of 97 % for R-citalopram upon introduction and 92 % for S-citalopram upon release.

2024-06-01·Computational biology and chemistry

Elucidation of escitalopram oxalate and related antidepressants as putative inhibitors of PTP4A3/PRL-3 protein in hepatocellular carcinoma: A multi-computational investigation

Article

作者: Mir, Ishfaq Hassan ; Kumar, Muthuvel Suresh ; Shyam, Kankipati Teja ; Ramesh, Thiyagarajan ; Balakrishnan, Susmida Seni ; Thirunavukkarasu, Chinnasamy

Hepatocellular carcinoma (HCC) persists to be one of the most devastating and deadliest malignancies globally. Recent research into the molecular signaling networks entailed in many malignancies has given some prominent insights that can be leveraged to create molecular therapeutics for combating HCC. Therefore, in the current communication, an in-silico drug repurposing approach has been employed to target the function of PTP4A3/PRL-3 protein in HCC using antidepressants: Fluoxetine hydrochloride, Citalopram, Amitriptyline, Imipramine, and Escitalopram oxalate as the desired ligands. The density function theory (DFT) and chemical absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters for the chosen ligands were evaluated to comprehend the pharmacokinetics, drug-likeness properties, and bioreactivity of the ligands. The precise interaction mechanism was explored using computational methods such as molecular docking and molecular dynamics (MD) simulation studies to assess the inhibitory effect and the stability of the interactions against the protein of interest. Escitalopram oxalate exhibited a comparatively significant docking score (-7.4 kcal/mol) compared to the control JMS-053 (-6.8 kcal/mol) against the PRL-3 protein. The 2D interaction plots exhibited an array of hydrophobic and hydrogen bond interactions. The findings of the ADMET forecast confirmed that it adheres to Lipinski's rule of five with no violations, and DFT analysis revealed a HOMO-LUMO energy gap of -0.26778 ev, demonstrating better reactivity than the control molecule. The docked complexes were subjected to MD studies (100 ns) showing stable interactions. Considering all the findings, it can be concluded that Escitalopram oxalate and related therapeutics can act as potential pharmacological candidates for targeting the activity of PTP4A3/PRL-3 in HCC.

项与草酸艾司西酞普兰相关的新闻（医药）

2024-09-23

·drugs

Psilocybin Equals or Exceeds SSRI Antidepressants at Easing Depression

MONDAY, Sept. 23, 2024 -- Psilocybin, the active ingredient in magic mushrooms, appears to ease depression symptoms at least as well as one of the most commonly used antidepressants , a new clinical trial shows. Patients showed significant improvement in their depressive symptoms after taking either a single dose of psilocybin or a six-week course of the SSRI antidepressant escitalopram ( Lexapro ), researchers reported Sept. 21 in the journal Lancet eClinicalMedicine1. They also presented the findings at the European College of Neuropsychopharmacology’s annual meeting in Milan. However, patients given psilocybin also reported additional long-term benefits, including a greater sense of meaning in life and better psychological connectedness to others. “Both treatments led to comparable improvements in alleviating symptoms of depression at the six-week mark, such as sadness and negative emotions,” said lead researcher Tommaso Barba , a doctoral candidate with Imperial College London in the U.K. “However, this work shows that psilocybin outperformed escitalopram in several measures of well-being, meaning in life, work and social functioning,” Barba said in a journal news release. “These results appeared to be maintained over a six-month follow-up period.” SSRI antidepressants like Prozac, Paxil and Zoloft are one of the main types of drugs used to treat depression, researchers said. However, about a third of patients don’t respond to treatment. “SSRIs work well, but not for everyone. They are also associated with some side effects,” Barba said. “This work implies that psilocybin generally seems to offer a real alternative, and perhaps additional benefits, to people who are worried about taking conventional antidepressants.” For the clinical trial, researchers recruited 59 patients with severe depression and assigned 30 to undergo a single psilocybin therapy session. The other 29 were prescribed escitalopram for six weeks. Up to six months later, patients in both groups showed similar improvements in their depression symptoms, researchers said. But only psilocybin produced additional benefits regarding well-being and meaning in life, they added. “This is important because improving connectedness and having greater meaning in life can significantly enhance a person's quality of life and long-term mental health,” said senior researcher Dr. David Erritzoe , clinical director of the Center for Psychedelic Research at Imperial College London. “The study suggests that psilocybin therapy might be a more holistic treatment option for depression, addressing both the symptoms of depression and overall well-being,” Erritzoe added. “This could make a substantial difference in the overall happiness and daily activities of those suffering from depression, providing a more joined-up approach to mental health treatment.” However, Erritzoe cautioned that psilocybin is still an experimental drug that’s administered in highly controlled environments, so people shouldn’t try using magic mushrooms to self-medicate at home. “These precautions are not found in recreational psychedelic use, which is known for having unpredictable and potentially harmful effects, especially for vulnerable people struggling with mental health issues,” Erritzoe said. Johan Lundberg , an adjunct professor of psychiatry with the Karolinska Institute in Stockholm, Sweden, agreed with Erritzoe’s caution regarding psilocybin use. “For now, we don’t know if psilocybin will be approved for the treatment of major depression, but if so, it won’t be for everyone,” said Lundberg, who was not involved in the research. “Some future patients might prefer psychedelic treatment over SSRI, but some patients may be intimidated by the dramatic alterations in perception and confrontations with challenging emotions that psychedelic drugs promote.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2024-09-23

·drugs

Could Antidepressants Give Memory a Boost?

MONDAY, Sept. 23, 2024 -- Antidepressants have the potential to improve memory and thinking skills, a new study suggests. Some patients experienced a boost on brain tests after taking the SSRI antidepressant escitalopram (Lexapro), researchers report. The drug appeared to affect a serotonin receptor in the brain called the 5HT4 receptor, according to results published recently in the journal Biological Psychiatry . Serotonin is described as a “feel good” hormone, researchers said in background notes. Higher levels of serotonin in the brain contribute to a sense of well-being and have been shown to ease clinical depression. “It seems that the SSRI medication contributes to an improvement on cognitive function, at the same time as helping improve mood,” said lead investigator Vibeke Dam , a senior researcher in neurology and neurobiology with Copenhagen University Hospital in Denmark. “Our work ties the improvement in cognitive function to the specific 5HT4 receptor and suggest that direct serotonin 4 receptor stimulation may be an important pro-cognitive target to consider in optimizing outcomes of antidepressant treatment,” Dam added in a journal news release. “It also reinforces the idea that serotonin is crucial to mood improvement." For the study, researchers scanned the brains of 90 depressed patients to measure 5HT4 receptor function in their brains. The patients also were tested for mood problems and cognitive abilities. Then the patients were given daily escitalopram (Lexapro) for eight weeks. At the end of the study, 40 patients were rescanned and retested. What did they find? The patients’ performance on cognitive tests had improved -- particularly their ability to recall words -- and this performance appeared to be linked to higher activity with the 5HT4 receptor. “This work points to the possibility of stimulating this specific receptor so that we can treat cognitive problems, even aside from whether or not the patient has overcome the core symptoms of depression,” said lead researcher Dr. Vibe Froekjaer , a clinical professor of neuropsychiatry with Copenhagen University Hospital in Denmark. The team’s next step will be to treat patients with drugs that specifically target the 5HT4 receptor, and then assess the effect on their brain function. Serotonin is found in the gut, and there are irritable bowel syndrome drugs that specifically bind to and stimulate 5HT4 receptors, researchers said. Researchers also presented these findings Monday at the European College of Neuropsychopharmacology’s annual meeting in Milan. The study “demonstrates the intimate role of brain 5HT4 receptors in cognitive function,” said Philip Cowen , a professor of psychopharmacology with the University of Oxford. “This confirms recent work from Oxford showing that the 5HT4 receptor stimulant, prucalopride -- a drug licensed for the treatment of constipation -- improves memory in both healthy participants and people at risk of depression,” said Cowen, who was not involved in the study. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024-09-12

·国家药品监督管理局

国家药监局公布药品说明书适老化及无障碍改革试点名单（第三批）

根据《国家药监局关于发布药品说明书适老化及无障碍改革试点工作方案的公告》（2023年第142号），省级药品监管部门和国家药监局药品审评中心报送了参与试点的药品上市许可持有人和药品名单（第三批），现予公布。序号药品名称上市许可持有人1利伐沙班片天津力生制药股份有限公司2缬沙坦氨氯地平片（I）天津力生制药股份有限公司3呋塞米片天津力生制药股份有限公司4氢氯噻嗪片天津力生制药股份有限公司5盐酸普萘洛尔片天津力生制药股份有限公司6复方丹参滴丸天士力医药集团股份有限公司7养血清脑丸天士力医药集团股份有限公司8养血清脑颗粒天士力医药集团股份有限公司9盐酸二甲双胍片津药达仁堂集团股份有限公司新新制药厂10安宫牛黄丸津药达仁堂集团股份有限公司达仁堂制药厂11牛黄清心丸（局方）津药达仁堂集团股份有限公司达仁堂制药厂12大活络丸津药达仁堂集团股份有限公司达仁堂制药厂13清宫寿桃丸津药达仁堂集团股份有限公司达仁堂制药厂14包醛氧淀粉散天津太平洋制药有限公司15阿莫西林胶囊天津太平洋制药有限公司16包醛氧淀粉胶囊天津太平洋制药有限公司17吲达帕胺缓释胶囊天津太平洋制药有限公司18诺氟沙星胶囊天津太平洋制药有限公司19补肾通淋颗粒天津太平洋制药有限公司20牛磺酸颗粒天津太平洋制药有限公司21银黄颗粒天津太平洋制药有限公司22甲硝唑片天津太平洋制药有限公司23阿昔洛韦片天津太平洋制药有限公司24氨咖甘片天津太平洋制药有限公司25二羟丙茶碱片天津太平洋制药有限公司26非普拉宗片天津太平洋制药有限公司27格列本脲片天津太平洋制药有限公司28尼群地平片天津太平洋制药有限公司29羧甲司坦片天津太平洋制药有限公司30硝苯地平片天津太平洋制药有限公司31硝酸异山梨酯片天津太平洋制药有限公司32盐酸二甲双胍片天津太平洋制药有限公司33扎来普隆片天津太平洋制药有限公司34吲达帕胺片天津太平洋制药有限公司35利巴韦林片天津太平洋制药有限公司36复方磺胺甲噁唑片天津太平洋制药有限公司37谷维素片天津太平洋制药有限公司38醋酸氟轻松乳膏天津太平洋制药有限公司39丁酸氢化可的松乳膏天津太平洋制药有限公司40哈西奈德乳膏天津太平洋制药有限公司41健儿消食口服液天津和治药业集团有限公司42麦味地黄口服液天津和治药业集团有限公司43清喉咽合剂天津和治药业集团有限公司44清热解毒口服液天津和治药业集团有限公司45生脉饮天津和治药业集团有限公司46小儿咳喘灵口服液天津和治药业集团有限公司47小儿退热口服液天津和治药业集团有限公司48川贝止嗽合剂天津和治药业集团有限公司49消食健胃片天津和治药业集团有限公司50活力源片天津和治药业集团有限公司51四季感冒片天津和治药业集团有限公司52穿黄清热胶囊天津和治药业集团有限公司53血府逐瘀软胶囊天津和治药业集团有限公司54盐酸氟桂利嗪胶囊石家庄市华新药业有限责任公司55诺氟沙星胶囊石家庄市华新药业有限责任公司56盐酸二甲双胍缓释片石家庄市华新药业有限责任公司57吲达帕胺片石家庄市华新药业有限责任公司58盐酸左氧氟沙星片石家庄市华新药业有限责任公司59盐酸左氧氟沙星胶囊石家庄市华新药业有限责任公司60缬沙坦氨氯地平片（I）石家庄市华新药业有限责任公司61阿奇霉素干混悬剂石家庄市华新药业有限责任公司62阿奇霉素片石家庄市华新药业有限责任公司63硝酸甘油片石家庄市华新药业有限责任公司64伏格列波糖片石家庄市华新药业有限责任公司65头孢克肟干混悬剂石家庄市华新药业有限责任公司66菖麻熄风片黑龙江省济仁药业有限公司67参鹿茶黑龙江省济仁药业有限公司68前列闭尔通栓黑龙江省济仁药业有限公司69痹痛宁胶囊黑龙江乌苏里江制药有限公司哈尔滨分公司70氯诺昔康片黑龙江乌苏里江制药有限公司哈尔滨分公司71人参五味子颗粒黑龙江乌苏里江制药有限公司哈尔滨分公司72益脑宁片黑龙江新医圣制药有限责任公司73刺五加片黑龙江新医圣制药有限责任公司74宁神灵颗粒黑龙江新医圣制药有限责任公司75复方苦木消炎胶囊黑龙江新医圣制药有限责任公司76盐酸凯普拉生片江苏柯菲平医药股份有限公司77瑞维鲁胺片江苏恒瑞医药股份有限公司78羟乙磺酸达尔西利片江苏恒瑞医药股份有限公司79番泻叶颗粒江苏艾迪药业股份有限公司80米氮平片华裕（无锡）制药有限公司81氨氯地平阿托伐他汀钙片昆山龙灯瑞迪制药有限公司82雷米普利片昆山龙灯瑞迪制药有限公司83尼麦角林片昆山龙灯瑞迪制药有限公司84云南白药膏云南白药集团无锡药业有限公司85云南白药创可贴云南白药集团无锡药业有限公司86盐酸氨基葡萄糖片江苏正大清江制药有限公司87厄贝沙坦氢氯噻嗪片江苏中治制药有限公司88阿哌沙班片南京正大天晴制药有限公司89芦比前列酮软胶囊南京正大天晴制药有限公司90奥美沙坦酯氨氯地平片江苏诺泰澳赛诺生物制药股份有限公司91噻托溴铵粉雾剂正大天晴药业集团股份有限公司92伏立康唑分散片扬子江药业集团南京海陵药业有限公司93左乙拉西坦片扬子江药业集团南京海陵药业有限公司94黄蜀葵花总黄酮口腔贴片杭州康恩贝制药有限公司95肾宝合剂浙江康恩贝中药有限公司96复方玄驹胶囊浙江施强制药有限公司97山海丹颗粒浙江施强制药有限公司98枸橼酸氢钾钠颗粒浙江施强制药有限公司99小儿咳喘灵口服液杭州华润老桐君药业有限公司100葡萄糖酸锌口服溶液杭州华润老桐君药业有限公司101百令胶囊杭州中美华东制药有限公司102泮托拉唑钠肠溶胶囊杭州中美华东制药有限公司103阿卡波糖片杭州中美华东制药有限公司104氨氯地平阿托伐他汀钙片瀚晖制药有限公司105海博麦布片浙江海正药业股份有限公司106盐酸多奈哌齐片浙江华海药业股份有限公司107草酸艾司西酞普兰片浙江华海药业股份有限公司108左乙拉西坦片浙江华海药业股份有限公司109奥氮平口崩片浙江华海药业股份有限公司110奥美沙坦酯氢氯噻嗪片浙江华海药业股份有限公司111阿立哌唑口崩片浙江华海药业股份有限公司112缬沙坦氢氯噻嗪片浙江华海药业股份有限公司113他达拉非片浙江华海药业股份有限公司114盐酸贝那普利片浙江华海药业股份有限公司115多巴丝肼片浙江华海药业股份有限公司116盐酸舍曲林片浙江华海药业股份有限公司117盐酸帕罗西汀片浙江华海药业股份有限公司118普瑞巴林胶囊浙江华海药业股份有限公司119赛洛多辛胶囊浙江华海药业股份有限公司120甲磺酸雷沙吉兰片浙江华海药业股份有限公司121福辛普利钠片浙江华海药业股份有限公司122利培酮片浙江华海药业股份有限公司123阿立哌唑片浙江华海药业股份有限公司124磷酸西格列汀片浙江华海药业股份有限公司125西格列汀二甲双胍片(II)浙江华海药业股份有限公司126硝苯地平控释片浙江华海药业股份有限公司127富马酸卢帕他定片浙江华海药业股份有限公司128维格列汀片浙江华海药业股份有限公司129恩格列净片浙江华海药业股份有限公司130托吡酯片浙江华海药业股份有限公司131沙库巴曲缬沙坦钠片浙江昂利康制药股份有限公司132头孢克洛颗粒浙江昂利康制药股份有限公司133盐酸左氧氟沙星片浙江昂利康制药股份有限公司134替格瑞洛片浙江昂利康制药股份有限公司135琥珀酸普芦卡必利片浙江昂利康制药股份有限公司136磷酸西格列汀片浙江昂利康制药股份有限公司137头孢氨苄胶囊浙江昂利康制药股份有限公司138聚卡波非钙片浙江昂利康制药股份有限公司139泊沙康唑肠溶片江西山香药业有限公司140甲苯磺酸索拉非尼片江西山香药业有限公司141醋酸阿比特龙片江西山香药业有限公司142艾司奥美拉唑镁肠溶片江西山香药业有限公司143盐酸坦索罗辛缓释胶囊江西山香药业有限公司144雷贝拉唑钠肠溶片江西山香药业有限公司145甲磺酸多沙唑嗪缓释片江西山香药业有限公司146甲磺酸仑伐替尼胶囊江西山香药业有限公司147马来酸阿法替尼片江西山香药业有限公司148哌柏西利胶囊江西山香药业有限公司149狗皮膏江西地康药业有限公司150海马万应膏江西地康药业有限公司151十全大补酒南昌恒湖药酒有限责任公司152人参药酒南昌恒湖药酒有限责任公司153枸杞药酒南昌恒湖药酒有限责任公司154周公百岁酒南昌恒湖药酒有限责任公司155史国公药酒南昌恒湖药酒有限责任公司156苯磺酸左氨氯地平片江西施美药业股份有限公司157辣椒风湿膏江西吉安三力制药有限公司158风茄平喘膏江西吉安三力制药有限公司159愈裂贴膏江西吉安三力制药有限公司160冻疮未溃膏江西吉安三力制药有限公司161伤疖膏江西吉安三力制药有限公司162曲安奈德新霉素贴膏江西吉安三力制药有限公司163恩替卡韦片江西制药有限责任公司164氟哌啶醇片江西制药有限责任公司165阿托伐他汀钙片江西制药有限责任公司166化积口服液江西诚志永丰药业有限责任公司167桔贝合剂江西诚志永丰药业有限责任公司168麻杏甘石合剂江西诚志永丰药业有限责任公司169鲜竹沥江西诚志永丰药业有限责任公司170生脉饮（党参方）江西诚志永丰药业有限责任公司171五子衍宗口服液江西诚志永丰药业有限责任公司172健儿清解液江西诚志永丰药业有限责任公司173肾宝合剂江西诚志永丰药业有限责任公司174清热解毒口服液江西诚志永丰药业有限责任公司175生脉饮江西诚志永丰药业有限责任公司176桂附地黄口服液江西诚志永丰药业有限责任公司177金钱通淋口服液江西诚志永丰药业有限责任公司178金果饮江西诚志永丰药业有限责任公司179麦味地黄口服液江西诚志永丰药业有限责任公司180杞菊地黄口服液江西诚志永丰药业有限责任公司181玉屏风口服液江西诚志永丰药业有限责任公司182四逆汤江西诚志永丰药业有限责任公司183小青龙合剂江西诚志永丰药业有限责任公司184他达拉非片南昌立健药业有限公司185枸橼酸西地那非片南昌立健药业有限公司186脑安滴丸安徽雷允上药业有限公司187脑安胶囊安徽雷允上药业有限公司188复方苁蓉益智胶囊安徽雷允上药业有限公司189再造生血胶囊安徽雷允上药业有限公司190再造生血片安徽雷允上药业有限公司191益气养血口服液安徽雷允上药业有限公司192黄厚止泻滴丸安徽雷允上药业有限公司193卡马西平片宜昌人福药业有限责任公司194维生素B2片宜昌人福药业有限责任公司195维生素B6片宜昌人福药业有限责任公司196非布司他片宜昌人福药业有限责任公司197琥珀酸美托洛尔缓释片宜昌人福药业有限责任公司198盐酸二甲双胍缓释片宜昌人福药业有限责任公司199萘普生钠片宜昌人福药业有限责任公司200枸橼酸托法替布缓释片宜昌人福药业有限责任公司201氨酚羟考酮片宜昌人福药业有限责任公司202盐酸羟考酮缓释片宜昌人福药业有限责任公司203奥卡西平片武汉人福药业有限责任公司204安立生坦片武汉人福药业有限责任公司205ω-3脂肪酸乙酯90软胶囊人福普克药业（武汉）有限公司206布洛芬软胶囊人福普克药业（武汉）有限公司207度他雄胺软胶囊人福普克药业（武汉）有限公司208艾地骨化醇软胶囊人福普克药业（武汉）有限公司209乙磺酸尼达尼布软胶囊人福普克药业（武汉）有限公司210甲硝唑片远大医药（中国）有限公司211他达拉非片远大医药（中国）有限公司212酒石酸美托洛尔片远大医药（中国）有限公司213磷酸奥司他韦颗粒宜昌东阳光长江药业股份有限公司214磷酸奥司他韦胶囊宜昌东阳光长江药业股份有限公司215替米沙坦片宜昌东阳光长江药业股份有限公司216替格瑞洛片宜昌东阳光长江药业股份有限公司217非布司他片宜昌东阳光长江药业股份有限公司218氟康唑胶囊宜昌东阳光长江药业股份有限公司219西格列汀二甲双胍片II宜昌东阳光长江药业股份有限公司220西格列汀二甲双胍片Ⅲ宜昌东阳光长江药业股份有限公司221磷酸奥司他韦干混悬剂宜昌东阳光长江药业股份有限公司222克拉霉素片宜昌东阳光长江药业股份有限公司223苯甲酸阿格列汀片宜昌东阳光长江药业股份有限公司224琥珀酸索利那新片宜昌东阳光长江药业股份有限公司225阿哌沙班片宜昌东阳光长江药业股份有限公司226七蕊胃舒胶囊健民药业集团股份有限公司227虚汗停糖浆健民药业集团股份有限公司228小儿紫贝宣肺糖浆健民药业集团股份有限公司229盐酸托莫西汀口服溶液健民药业集团股份有限公司230拉考沙胺口服溶液健民药业集团股份有限公司231硫酸特布他林健民药业集团股份有限公司232马来酸噻吗洛尔滴眼液武汉新瑞医药科技有限公司233溴芬酸钠滴眼液武汉五景药业有限公司234阿莫西林胶囊湖南科伦制药有限公司235康复新液湖南科伦制药有限公司236泊沙康唑口服混悬液湖南科伦制药有限公司237血塞通片湖南绅泰春制药股份有限公司238六味地黄丸（浓缩丸）九芝堂股份有限公司239杞菊地黄丸（浓缩丸）九芝堂股份有限公司240驴胶补血颗粒九芝堂股份有限公司241蒙脱石散江右制药（常德）有限公司242复方金银花颗粒江右制药（常德）有限公司243风热感冒颗粒江右制药（常德）有限公司244前列癃闭通片江右制药（常德）有限公司245复方雪莲烧伤膏江右制药（常德）有限公司246四消丸江右制药（常德）有限公司247阿胶山东喜君康医药集团湘潭有限公司248苯磺酸氨氯地平片湖南千金协力药业有限公司249恩替卡韦分散片湖南千金协力药业有限公司250硫酸氨基葡萄糖胶囊湖南先施制药有限公司251古汉养生精口服液古汉中药有限公司252古汉养生精片古汉中药有限公司253枸橼酸西地那非片广州朗圣药业有限公司254他达拉非片广州朗圣药业有限公司255双氯芬酸钠缓释片国药集团致君（深圳）坪山制药有限公司256奥美沙坦酯氨氯地平片国药集团致君（深圳）坪山制药有限公司257依托考昔片国药集团致君（深圳）制药有限公司258左乙拉西坦片深圳信立泰药业股份有限公司259左乙拉西坦缓释片深圳信立泰药业股份有限公司260艾司奥美拉唑镁肠溶胶囊广东东阳光药业股份有限公司261奥氮平口崩片广东东阳光药业股份有限公司262富马酸喹硫平片广东东阳光药业股份有限公司263奥美沙坦酯片东莞市阳之康医药有限责任公司264盐酸莫西沙星片东莞市阳之康医药有限责任公司265阿立哌唑口崩片东莞市阳之康医药有限责任公司266阿立哌唑片东莞市阳之康医药有限责任公司267草酸艾司西酞普兰片东莞市阳之康医药有限责任公司268盐酸度洛西汀肠溶胶囊东莞市阳之康医药有限责任公司269厄贝沙坦胶囊珠海润都制药股份有限公司270厄贝沙坦氢氯噻嗪片珠海润都制药股份有限公司271复方丹参片广州白云山和记黄埔中药有限公司272脑栓通胶囊广东华南药业集团有限公司273盐酸安非他酮缓释片万特制药（海南）有限公司274阿立哌唑口服溶液万特制药（海南）有限公司275盐酸莫西沙星片重庆华邦制药有限公司276利伐沙班片重庆华邦制药有限公司277苯磺贝他斯汀片重庆华邦制药有限公司278萘替芬酮康唑乳膏重庆华邦制药有限公司279维A酸乳膏重庆华邦制药有限公司280盐酸左西替利嗪口服溶液重庆华邦制药有限公司281盐酸左西替利嗪片重庆华邦制药有限公司282阿伐斯汀胶囊重庆华邦制药有限公司283阿维A胶囊重庆华邦胜凯制药有限公司284异维A酸软胶囊重庆华邦胜凯制药有限公司285地奈德乳膏重庆华邦胜凯制药有限公司286甘桔冰梅片重庆华森制药股份有限公司287痛泻宁颗粒重庆华森制药股份有限公司288都梁软胶囊重庆华森制药股份有限公司289八味芪龙颗粒重庆华森制药股份有限公司290铝碳酸镁片重庆华森制药股份有限公司291铝碳酸镁咀嚼片重庆华森制药股份有限公司292奥美拉唑碳酸氢钠胶囊重庆华森制药股份有限公司293奥美沙坦酯氨氯地平片重庆华森制药股份有限公司294小金片太极集团重庆桐君阁药厂有限公司295苏合香丸太极集团重庆桐君阁药厂有限公司296沉香化气片太极集团重庆桐君阁药厂有限公司297强力天麻杜仲丸太极集团重庆桐君阁药厂有限公司298麻仁丸太极集团重庆桐君阁药厂有限公司299安宫牛黄丸太极集团重庆桐君阁药厂有限公司300还少丹（大蜜丸）太极集团重庆桐君阁药厂有限公司301还少丹太极集团重庆桐君阁药厂有限公司302归脾合剂太极集团重庆桐君阁药厂有限公司303桔贝合剂太极集团重庆桐君阁药厂有限公司304拨云退翳丸太极集团重庆桐君阁药厂有限公司305藿香正气口服液太极集团重庆涪陵制药厂有限公司306通天口服液太极集团重庆涪陵制药厂有限公司307急支糖浆太极集团重庆涪陵制药厂有限公司308急支颗粒太极集团重庆涪陵制药厂有限公司309补肾益寿胶囊太极集团重庆涪陵制药厂有限公司310丹参口服液太极集团重庆涪陵制药厂有限公司311盐酸文拉法辛片重庆药友制药有限责任公司312吲达帕胺片重庆药友制药有限责任公司313复方对乙酰氨基酚片（II）西南药业股份有限公司314布洛芬缓释片西南药业股份有限公司315维生素C咀嚼片西南药业股份有限公司316左氧氟沙星片四川新斯顿制药股份有限公司317塞来昔布胶囊四川新斯顿制药股份有限公司318盐酸氨基葡萄糖片四川新斯顿制药股份有限公司319苯酰甲硝唑分散片四川新斯顿制药股份有限公司320氯雷他定口腔崩解片四川新斯顿制药股份有限公司321盐酸美金刚片四川新斯顿制药股份有限公司322左氧氟沙星滴眼液四川美大康华康药业有限公司323盐酸莫西沙星滴眼液四川美大康华康药业有限公司324伏立康唑片四川美大康华康药业有限公司325来那度胺胶囊四川美大康华康药业有限公司326普乐安片云南白药集团股份有限公司327藿香正气胶囊云南白药集团股份有限公司328复方丹参片云南白药集团股份有限公司329六味地黄胶囊云南白药集团股份有限公司330关节止痛膏云南白药集团股份有限公司331伤湿止痛膏云南白药集团股份有限公司332麝香跌打风湿膏云南白药集团股份有限公司333一枝蒿伤湿祛痛膏云南白药集团股份有限公司334参苓健脾胃颗粒云南白药集团股份有限公司335宫血宁胶囊云南白药集团股份有限公司336痛舒胶囊云南白药集团股份有限公司337三七参蜂口服液云南白药集团股份有限公司338伤风停胶囊云南白药集团股份有限公司339丹溪玉屏风颗粒云南白药集团股份有限公司340风热感冒颗粒云南白药集团股份有限公司341四季感冒片云南白药集团股份有限公司342妇炎康片云南白药集团股份有限公司343痛舒片云南白药集团股份有限公司344消炎退热颗粒云南白药集团股份有限公司345板蓝根颗粒云南白药集团股份有限公司346热毒清片云南白药集团股份有限公司347玄麦甘桔颗粒云南白药集团股份有限公司348天紫红女金胶囊云南白药集团股份有限公司349小儿健脾平肝颗粒云南白药集团股份有限公司350小儿七星茶颗粒云南白药集团股份有限公司351止泻保童颗粒云南白药集团股份有限公司352泻痢消胶囊云南白药集团股份有限公司353生脉饮（党参方）云南白药集团股份有限公司354肿痛气雾剂云南白药集团股份有限公司355伤益气雾剂云南白药集团股份有限公司356利儿康口服液云南白药集团股份有限公司357陈香露白露片云南白药集团大理药业有限责任公司358气血康口服液云南白药集团文山七花有限责任公司359血塞通软胶囊昆药集团股份有限公司360血塞通片云南维和药业股份有限公司361血塞通胶囊云南维和药业股份有限公司362血塞通颗粒云南维和药业股份有限公司363盐酸莫西沙星片Bayer Vital GmbH364屈螺酮炔雌醇片Bayer Australia Ltd365琥珀酸索利那新片Astellas Pharma Europe B.V.366盐酸普拉克索片Boehringer Ingelheim International GmbH367达比加群酯胶囊Boehringer Ingelheim International GmbH368盐酸普拉克索缓释片Boehringer Ingelheim International GmbH369马来酸阿法替尼片Boehringer Ingelheim International GmbH

100 项与草酸艾司西酞普兰相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02567	草酸艾司西酞普兰	N06AB10	DB01175

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
强迫症	澳大利亚	Generic Health Pty Ltd.	2018-02-23
社交恐怖症	日本	Mochida Pharmaceutical Co., Ltd.	2015-11-20
社交恐怖症	日本	H. Lundbeck A/S	2015-11-20
社交恐怖症	日本	Yoshitomi Co., Ltd.	2015-11-20
社交恐怖症	日本	Mitsubishi Tanabe Pharma Corp.	2015-11-20
抑郁症	中国	H. Lundbeck A/S	2005-08-31
惊恐障碍	中国	H. Lundbeck A/S	2005-08-31
广泛性焦虑障碍	美国	AbbVie, Inc.	2003-12-18
重度抑郁症	美国	AbbVie, Inc.	2002-08-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
获得性免疫缺陷综合征	临床3期	美国	Forest Laboratories, Inc.	2009-05-01
精神分裂症	临床3期	以色列	Lundbeck LLC	2004-11-01
行为障碍	临床2期	美国	Forest Laboratories, Inc.	2010-04-01
创伤性脑损伤	临床2期	美国	Forest Laboratories, Inc.	2010-04-01
皮肤潮红	临床2期	加拿大	H. Lundbeck A/S	2008-10-01
慢性丙型肝炎	临床2期	西班牙	H. Lundbeck A/S	2005-03-01
焦虑症	临床1期	加拿大	H. Lundbeck A/S	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02620150 (CTgov)	临床4期	抑郁症 \| 获得性免疫缺陷综合征	108	Escitalopram (Experimental)	鏇齋網襯膚餘齋膚憲夢(艱淵壓簾鹽製鑰製膚構) = 鏇淵鑰遞蓋觸衊衊築襯積鹽襯構遞淵獵憲顧憲 (願築築窪膚觸遞範艱艱, 憲鹹艱構遞夢網艱糧醖 ~ 膚網築製鹹選窪窪蓋膚) 更多	-	2024-05-07
				Placebo (Placebo)	鏇齋網襯膚餘齋膚憲夢(艱淵壓簾鹽製鑰製膚構) = 鬱餘製顧淵觸繭廠壓鬱積鹽襯構遞淵獵憲顧憲 (願築築窪膚觸遞範艱艱, 膚獵遞淵醖蓋鑰鹹壓鹹 ~ 艱淵蓋夢網積選簾鑰淵) 更多
NCT03993457 (PRECISE-D, CTgov)	临床4期	抑郁症	18	Escitalopram (CRP<1, CRP Consistent Antidepressant Selection)	襯範築繭憲壓願艱積鏇(衊鹽顧糧蓋選積糧鹽築) = 鏇觸廠鹽窪鏇衊製鬱夢鏇願蓋觸鹽繭鬱壓鬱積 (製膚壓襯蓋繭餘鹽淵簾, 衊遞糧積製繭鬱繭選鹽 ~ 齋獵鬱艱艱壓鬱網衊齋) 更多	-	2023-04-18
				Bupropion (CRP> or Equal to 1, CRP Consistent Antidepressant Selection)	襯範築繭憲壓願艱積鏇(衊鹽顧糧蓋選積糧鹽築) = 獵範願簾觸網齋鏇顧簾鏇願蓋觸鹽繭鬱壓鬱積 (製膚壓襯蓋繭餘鹽淵簾, 餘衊醖蓋製夢襯襯選築 ~ 網網獵觸窪窪獵網衊願) 更多
NCT03924323 (CTgov)	临床4期	广泛性焦虑障碍	273	Placebo (Placebo)	積選窪膚選選簾顧壓製(膚構衊觸淵窪淵獵鬱齋) = 鏇鏇蓋淵鹹醖觸糧艱淵窪襯簾築遞夢廠製壓夢 (築膚淵顧夢夢鏇衊糧製, 夢窪獵鏇糧簾製鏇顧衊 ~ 淵廠蓋糧襯襯鏇廠鑰醖) 更多	-	2022-11-14
				Escitalopram (Escitalopram 10 mg/Day)	積選窪膚選選簾顧壓製(膚構衊觸淵窪淵獵鬱齋) = 衊衊觸製艱觸膚簾顧膚窪襯簾築遞夢廠製壓夢 (築膚淵顧夢夢鏇衊糧製, 鏇獵範願窪鑰顧築獵獵 ~ 餘夢鏇願範齋鹹憲遞網) 更多
NCT02674529 (SONRISA, CTgov)	临床2/3期	重度抑郁症	60	escitalopram+Real-time Neurofeedback fMRI task pre- (Antidepressant Treatment)	鹽選糧範襯製觸襯網醖(餘顧醖顧淵廠醖壓膚簾) = 襯壓衊壓網膚衊鹹構願遞壓襯製鬱鏇製構願淵 (鹽壓鏇壓膚蓋願選構廠, 夢廠顧選鏇繭鬱膚顧壓 ~ 醖繭遞構獵齋遞膚廠簾) 更多	-	2022-11-03
				Real-time Neurofeedback fMRI task pre- (Placebo)	鹽選糧範襯製觸襯網醖(餘顧醖顧淵廠醖壓膚簾) = 鹽製醖膚淵淵襯簾鬱窪遞壓襯製鬱鏇製構願淵 (鹽壓鏇壓膚蓋願選構廠, 廠艱製衊糧選衊網廠廠 ~ 衊壓獵糧獵夢糧遞鑰衊) 更多
NCT02623205 (CTgov)	临床4期	抑郁症	85	Escitalopram (Escitalopram)	壓鏇淵網遞鏇淵鏇壓襯(繭衊醖膚鑰鬱艱壓衊簾) = 憲繭壓齋築繭淵鹽觸餘蓋願選鹽簾構壓淵鹹鹽 (廠壓簾觸廠繭獵築餘憲, 選餘衊醖顧鏇顧鬱餘艱 ~ 淵築夢製鬱鏇淵蓋構構) 更多	-	2022-06-02
				Placebo (Placebo)	壓鏇淵網遞鏇淵鏇壓襯(繭衊醖膚鑰鬱艱壓衊簾) = 網觸顧觸鏇選繭繭鑰鏇蓋願選鹽簾構壓淵鹹鹽 (廠壓簾觸廠繭獵築餘憲, 積夢餘淵顧壓鹽衊獵鹹 ~ 範顧憲夢憲衊壓壓壓獵) 更多
NCT03812588 (CTgov)	临床4期	重度抑郁症	29	Placebo (Clinical Frequency Management: Placebo)	夢範窪選鬱廠鑰艱鏇鬱(齋鹽簾製夢獵鏇廠鹽艱) = 遞淵鬱窪淵鹽衊構選觸憲製網鏇製鹹觸觸願齋 (膚艱廠淵壓繭糧積顧鹹, 觸範廠鏇鏇鑰積醖壓蓋 ~ 齋鬱築糧鹽廠製鑰繭艱) 更多	-	2022-04-21
				Placebo (Research Frequency Management: Placebo)	夢範窪選鬱廠鑰艱鏇鬱(齋鹽簾製夢獵鏇廠鹽艱) = 夢窪製繭鑰廠鏇醖淵淵憲製網鏇製鹹觸觸願齋 (膚艱廠淵壓繭糧積顧鹹, 觸鑰遞遞糧觸淵廠築鏇 ~ 選觸壓壓選觸鏇淵衊鹽) 更多
NCT04697693 (CTgov)	临床4期	重度抑郁症 \| 创伤后应激障碍	1	Escitalopram+Duloxetine	網淵選積鹽鬱夢糧遞鹹(鏇構獵願鏇廠淵鹽艱醖) = 蓋餘餘齋願築積顧齋蓋艱膚鹹鹽選觸醖鏇選願 (遞觸窪夢積衊觸鬱蓋構, 鬱餘簾艱鹹憲衊繭簾夢 ~ 製鑰觸構構窪鏇選選膚) 更多	-	2022-03-28
NCT02332291 (CAARE, CTgov)	临床4期	重度抑郁症	95	Bupropion XL+escitalopram (Blinded Escitalopram / Open-Label Bupropion)	鏇觸願餘鹽願廠網願鬱(膚鏇製範淵襯醖糧廠簾) = 鑰鬱蓋壓選顧遞鏇淵齋簾鑰製遞繭鹹顧遞鏇衊 (願膚糧鏇構鏇築壓壓壓, 壓鹹鹹網選醖鑰構蓋艱 ~ 鹽築壓積壓鹹齋積淵蓋)	-	2021-09-21
				Bupropion XL (Blinded Placebo / Open-Label Bupropion)	鏇觸願餘鹽願廠網願鬱(膚鏇製範淵襯醖糧廠簾) = 糧獵衊築襯夢鏇壓淵製簾鑰製遞繭鹹顧遞鏇衊 (願膚糧鏇構鏇築壓壓壓, 醖壓齋鬱窪網築選醖製 ~ 衊願蓋網鹽網齋遞選簾)
NCT03321006 (CTgov)	临床4期	认知功能障碍 \| 抑郁症 \| 老年性耳聋	25	escitalopram+Audeo B-R 90 hearing aid device (Sham)+Duloxetine (Antidepressant (AD) + Low Amplification (Sham) Hearing Aids)	積窪觸選鑰構夢遞範廠(範顧壓齋鑰築窪觸選齋) = 餘醖艱網襯襯蓋廠觸選獵鬱艱願窪壓遞淵餘積 (獵艱築蓋鏇艱觸遞齋選, 願憲積構遞醖簾憲鹹憲 ~ 築積範襯襯觸餘衊範艱) 更多	-	2021-08-19
				escitalopram+Phonak Audeo B-R 90 hearing aid device (Active)+Duloxetine (Antidepressant (AD) + Full Amplification Hearing Aids)	積窪觸選鑰構夢遞範廠(範顧壓齋鑰築窪觸選齋) = 鑰襯顧製遞製簾廠膚範獵鬱艱願窪壓遞淵餘積 (獵艱築蓋鏇艱觸遞齋選, 夢壓鬱壓襯製獵壓艱襯 ~ 願鑰鑰網廠製憲繭鬱遞) 更多
NCT02516332 (CTgov)	N/A	心血管疾病 \| 焦虑症	128	Supervised Aerobic Exercise (Supervised Aerobic Exercise)	壓鏇簾顧鹹範獵廠簾襯(顧觸憲淵鏇觸築願壓簾) = 糧憲齋獵壓蓋鹽顧膚糧顧繭窪簾廠餘簾鹹衊淵 (醖觸餘廠壓網製簾選鬱, 積鬱淵範網鏇齋廠醖鹽 ~ 顧願獵蓋觸餘積遞簾選) 更多	-	2021-06-11
				Lexapro (Lexapro)	壓鏇簾顧鹹範獵廠簾襯(顧觸憲淵鏇觸築願壓簾) = 獵壓鏇顧襯蓋構鹽襯窪顧繭窪簾廠餘簾鹹衊淵 (醖觸餘廠壓網製簾選鬱, 選簾醖製襯選窪襯淵餘 ~ 壓鏇襯選壓鹹遞築觸膚) 更多